AI Bias Analysis
4 models · Takes ~15 seconds
The Swiss drugmaker Roche presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval.
Source
Stat News
Opens original article in a new tab
A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a generation beyond.
A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in a late-stage trial.
At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared the state of cancer research steady.
(MedPage Today) -- The FDA approved islatravir-doravirine (Idvynso) as a standalone, single-tablet regimen for treating HIV in virologically suppressed adults, Merck announced on Tuesday. Approval stipulates use of the oral combination in patients...
